Surgeons at Mercy Medical Center in Cedar Rapids Preserve More Breast Tissue and Reduce the Need for Additional Surgery by 75% for Breast Cancer Patients with Targeted Excision Using MarginProbe®
FDA approved device enables surgeons to preserve more breast tissue while reducing the need for additional surgery according to medical study.
According to a New Clinical Study MarginProbe® Reduces Re-Excision Rate by Half Following Lumpectomies; For DCIS, by Over 60%
MarginProbe provides breast cancer surgeons with real-time information during lumpectomies to help decide whether additional tissue should be excised.
Surgeon Spotlight: Dr. Jeffrey Falk – Early Study Data Supports the Value of MarginProbe® in Getting All the Cancer in the First Lumpectomy Surgery
Dr. Jeffrey Falk is a surgical oncologist focusing primarily on breast cancer since starting his practice in 2001. He performs 200-350 breast cancer surgeries annually and has a special interest in research and clinical trials for breast cancer treatments.
Emerging Technologies Impacting Cancer Care: How Dune Medical is Helping Surgeons Identify Additional Cancer in the Operating Room
MarginProbe® recognized as a noteworthy medical device for helping reduce positive margins for lumpectomy surgeries by Tim Clay during an interview for News Medical Life Sciences.
MarginProbe® Shrinks Positive Margin Rates and Tissue Volume Removed for Both Invasive and DCIS Breast Cancers
Dr. Reid is a firm believer in the success of MarginProbe in improving the results of breast cancer surgery.
Physician Insight for Patients: Dr. Vincent Reid – MarginProbe® Shrinks Positive Margin Rates and Tissue Volume Removed for Both Invasive and DCIS Breast Cancers
MarginProbe® Gives Patients the Best Chance for Only One Lumpectomy Procedure for Both Invasive and DCIS Breast Cancers
Healthcare Reporter Lucette Lagnado profiles MarginProbe® in The Wall Street Journal featuring Dr. Freya Schnabel, Dr. Alice Police, Dr. Vincent Reid, Dune Medical CEO Lori Chmura and more.
For more than three decades, the annual Miami Breast Cancer Conference (MBCC) has brought together…
Collectively improving the standard of breast cancer treatment at ASBrS 2017 About the American Society…
Dr. Beth-Ann Lesnikoski explains the advantages of MarginProbe as compared to Full Cavity Shavings.
With sustainability in mind, Dune designed a reposable version of MarginProbe. The new reposable MarginProbe has a reusable cable and handle and a single-use attachable probe. The new probe has the potential to reduce waste burden of MarginProbe up to 50%.
It’s been one year since our relocation to Atlanta in August 2017. We have been incredibly busy these past 12 months, and here are some of the highlights!
Radio-Frequency Spectroscopy Platform Development Enters Feasibility Testing Phase Supported by Prestigious Horizon 2020 Grant
Capitalizing on the European Union Horizon 2020 research and innovation program, Dune Medical has completed the first phase in the development of its percutaneous soft tissue biopsy device.
Dune Medical teams up with Margie’s Army and AreYouDense advocacy to give women with dense breasts access to an earlier diagnosis of their breast cancer
Breast density is one of the most common reasons for failure of mammography to detect cancer and presents unique challenges for breast cancer patients and providers. Despite being a well-established independent risk factor for breast cancer(1), 95% of women do not know their breast density.
Do you want to be up to date?